{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:35:10Z","timestamp":1793885710193,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015322","name":"National Cancer Center Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.06.049","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:48:23Z","timestamp":1782949703000},"page":"1493.e1-1493.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Use of Maribavir for Refractory CMV Infection and Intolerance to Conventional Anti-CMV Agents After Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"given":"Risa","family":"Nishiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-6357","authenticated-orcid":false,"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-9340","authenticated-orcid":false,"given":"Yu","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4932-405X","authenticated-orcid":false,"given":"Sumiko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Shibano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuto","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneaki","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4038-724X","authenticated-orcid":false,"given":"Wataru","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-3349","authenticated-orcid":false,"given":"Keiji","family":"Okinaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jtct.2026.06.049_bib0001","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on infections in leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.jtct.2026.06.049_bib0002","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol Blood Marrow transplant J Am Soc Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.jtct.2026.06.049_bib0003","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.049_bib0004","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1093\/cid\/ciaa1871","article-title":"Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality","volume":"73","author":"Akahoshi","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"23","key":"10.1016\/j.jtct.2026.06.049_bib0005","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.049_bib0006","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev Med Virol"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.049_bib0007","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol Offic Publicat Pan Am Soc Clin Virol"},{"issue":"8","key":"10.1016\/j.jtct.2026.06.049_bib0008","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.049_bib0009","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.049_bib0010","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2026.06.049_bib0011","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections, 2026. https:\/\/www.nccn.org. Accessed May 8, 2026"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.049_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14444","article-title":"Real-world experience with maribavir for treatment of refractory or resistant cytomegalovirus infection in hematopoietic cell transplant recipients and hematologic malignancy patients","volume":"27","author":"Daher","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2026.06.049_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2026.15769","article-title":"Use of maribavir in adult patients with post-transplant refractory cytomegalovirus infection in the real-life setting","volume":"39","author":"Kamar","year":"2026","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.049_bib0014","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jtct.2026.06.049_bib0015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.06.049_bib0016","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.06.049_bib0017","unstructured":"Maertens J, Berm\u00fadez A, Peggs KS, et al. Real-world use, effectiveness and safety of maribavir in hematopoietic cell transplant recipients with refractory\/resistant CMV or intolerance to anti-CMV agents: interim ARISE results. 2026"},{"key":"10.1016\/j.jtct.2026.06.049_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(26)00144-1","article-title":"Maribavir for clinically significant cytomegalovirus infection in haematopoietic cell transplant recipients in Europe: a real-world multicentre retrospective registry study","author":"Paviglianiti","year":"2026","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.049_bib0019","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.06.049_bib0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12185-021-03218-3","article-title":"Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation","volume":"115","author":"Jinnouchi","year":"2022","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.06.049_bib0021","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients","volume":"229","author":"Chou","year":"2024","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2026.06.049_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29609","article-title":"Cost-effectiveness of maribavir versus conventional antiviral therapies for post-transplant refractory cytomegalovirus infection with or without genotypic resistance: a US perspective","volume":"96","author":"Schultz","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.jtct.2026.06.049_bib0023","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Review report for maribavir (Livtencity tablets 200 mg). 2024.https:\/\/www.pmda.go.jp\/drugs\/2024\/P20240628002\/400256000_30600AMX00161_A100_1.pdf. Accessed May 8, 2026"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:18:20Z","timestamp":1793884700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666636726005269"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.049","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Use of Maribavir for Refractory CMV Infection and Intolerance to Conventional Anti-CMV Agents After Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.06.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}